Indian Medtech Startup Sigtuple Receives U.S. FDA approval; becomes India's 1st company in this space to earn the clearance

▴ SigTuple
For all haematological disorders like blood cancers, infections, anaemia & allergies, the microscopic examination of the peripheral blood smear (PBS) is the gold standard test, but microscopy today is predominantly a manual process - necessitating a highly skilled pathologist to be present on-site.

Bangalore, October 3, 2023: SigTuple, a medtech company that develops Artificial Intelligence (AI) powered digital microscopy solutions, announced that its path-breaking device AI100 with ShonitTM (Peripheral blood smear application) has received U.S. FDA 510(k) clearance. This is the first integrated hardware and AI medical device, and the first product in AI-assisted digital microscopy from India to obtain the coveted clearance and one of the handfuls of companies in the world to obtain it. 

SigTuple’s AI100 with ShonitTM is the premier solution for AI-assisted digital pathology, wherein a physical sample is digitally imaged through a microscopic lens & the AI models extract each cell and then classify it into over 30 different cell types. The pathologists can now review the samples remotely. Further, the AI helps make the pathologist more efficient, by automating most of the review. Thus, the same pathologist can now handle a much larger number of samples than she can currently, eliminating the need for an additional manual review.

Apurv Manjrekar, Chief Product Officer - SigTuple said, “SigTuple AI100 with ShonitTM automates one of the last remaining pieces of manual processes in a clinical laboratory – that of microscopic review of blood samples to detect various diseases. AI100 with ShonitTM is the first integrated hardware and AI medical device, and the first product in AI-assisted digital microscopy from India to obtain the US FDA 510(k) clearance. Even globally, US FDA clearances for digital microscopy products are few and far between. SigTuple thus finds its place among a handful of global elites to have achieved this milestone.”

Tathagato Rai Dastidar, Founder & CEO - SigTuple said, “This is a watershed moment for us – to have the quality and efficacy of our product validated and approved by one of the most stringent medical regulatory authorities in the world. This opens multiple new doorways for us to expand internationally, and build a global medical technology company out of India. The process also gave us invaluable experience on how to navigate the regulatory pathways, and this will prove to be an asset as we take our upcoming products through the approval processes”

While AI-powered digital microscopy solutions have existed for over 15 years, the technology has barely seen any meaningful traction. The abysmal low adoption could be because of lack of localisation, unaffordable pricing & inability of the incumbent’s AI to work with variation in sample quality.  AI100 addresses each of the above points holistically and is the only digital pathology solution available, which is economical and robust enough for wide-scale adoption.

About SigTuple

SigTuple is revolutionising pathology through robotics and advanced AI. We make the life of the pathologist easier, and thereby improve patient outcomes, by automating the inefficient and error-prone manual microscopic review process for the most common tests – blood and urine microscopy. We offer a software solution. The hardware is an automated slide scanner, capable of converting any physical specimen into digital images. The AI platform analyses these images and provides clinical insights into the sample, which brings down slide review time for the pathologist, and allows her to seamlessly work remotely or collaborate with other medical experts across geographies.

Tags : #SigTuple #medtech #USA #FDA #startupindia #clearance #AI #medicaldevice #medicircle

About the Author


Sunny Parayan

Hey there! I'm Sunny, a passionate writer with a strong interest in the healthcare domain! When I'm not typing on my keyboard, I watch shows and listen to music. I hope that through my work, I can make a positive impact on people's lives by helping them live happier and healthier.

View Profile

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

Healthcare Startups to Watch Out for in 2025December 20, 2024
Biobank Blueprint: Redefining Diabetes Diagnosis and Treatment in IndiaDecember 20, 2024
The Future of Malaria Prevention: Can This Vaccine Eliminate the Disease?December 20, 2024
Why the World Trusts Indian Pharmaceuticals for Life-Saving SolutionsDecember 20, 2024
International Tsunami Conference Concludes at AmritapuriDecember 20, 2024
Prestige Marks 75 Years of Revolutionizing Home Cooking with Iconic Innovative ProductsDecember 20, 2024
Revolutionizing Education: Online Learning Platforms Transforming Study Materials for Board and Competitive ExamsDecember 19, 2024
Why Your Blood Pressure Reading Might Be a Lie and How to Fix ItDecember 19, 2024
Vaccines, Cards, and Digital Records: How India is Fighting Healthcare InequalityDecember 19, 2024
Bridging Borders: Sri Lanka’s President Explores India’s Healthcare and HeritageDecember 19, 2024
Jeevan Jyoti Project Brings Eye Care to Alwar's Rural CommunitiesDecember 19, 2024
Crompton Launches New Range of Decorative Wall Lights Providing a Perfect Blend of Uniqueness & AestheticsDecember 19, 2024
Can One Injection End Decades of HIV Inequality?December 19, 2024
Multi-Organ Marvel: How a 12-Hour Surgery Gave a Businessman New LifeDecember 19, 2024
Jupiter Hospital Celebrates BMT Heroes: Honoring Patients, Donors, and Advancing Care with New MilestonesDecember 18, 2024
Beware of Fraudulent Activities in the Name of Asian HospitalDecember 17, 2024
Why Feeling Lonely Can Be as Dangerous as Smoking for Your BrainDecember 17, 2024
Rethinking Intelligence: How Brain Connectivity Defines Our Intellectual PotentialDecember 17, 2024
Lonely in a Crowd: When Socializing Fails to Heal Young MindsDecember 17, 2024
How many hours of sleep are children getting on average now compared to before the pandemic?December 17, 2024